Precigen Receives the US FDA’s IND Clearance of PRGN-2009 + Pembrolizumab for the Treatment of Recurrent or Metastatic Cervical Cancer
Shots:
- The US FDA has cleared the IND application to initiate a P-II study evaluating PRGN-2009 (off-the-shelf AdenoVerse immunotherapy) + pembrolizumab vs pembrolizumab monotx. in a ratio (1:1) in ~46 patients
- The primary objective of the P-II study is to evaluate the ORR following treatment with PRGN-2009 + pembrolizumab over pembrolizumab monotx. while the secondary objectives incl. the evaluation of safety, tolerability, PFS, OS, BOR, DCR, time to response & DoR
- The interim P-I results showed a favorable safety profile of PRGN-2009 as monotx. & combination with a checkpoint inhibitor, ORR (30%) with no DLTs along with encouraging clinical activity in patients with heavily pre-treated HPV-associated cancers
Ref: PRNewswire | Image: Precigen
Related News:- Microbiotica Entered into a Clinical Trial Collaboration Agreement with MSD to Evaluate MB097 + Keytruda (pembrolizumab) for Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
